阿戈美拉汀治疗抑郁症的临床研究

Abstract
Figure/Table
References (18)
Related Citation (15)

Download: PDF (0 KB) HTML (34 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect and safety of Agomelatine in the treatment of depression.Methods A total of 197 patients with depression in Ganzhou People′s Hospital from June 2017 to December 2018 were selected as the research objects, according to the double-blind random method, they were divided into the observation group (101 cases, 3 cases of shedding and the rest 98 cases) and the control group (96 cases, 2 cases of shedding and the rest 94 cases).The control group was treated with Paroxetine, and the observation group was treated with Agomelatine.The clinical effective rate, Hamilton depression scale (HAMD) score and adverse reactions were compared between the two groups.Results The clinical effective rate of the observation group was 91.84%, compared with 93.62% of the control group, the difference was not statistically significant (P＞0.05).The HAMD scores of the two groups at the end of the 2nd and 4th weeks were lower than those before treatment, and the HAMD scores of the observation group at the end of the 2nd and 4th weeks were lower than those of the control group, the differences were statistically significant (P＜0.05).There were no significant differences in the incidence of sleep disorders, upright collapse, physical fatigue, headache, palpitation, tremor, dysuria, sweating, dry mouth, constipation, sleepiness and other adverse reactions between the two groups(P＞0.05).The incidence of sexual dysfunction in the observation group was lower than that in the control group, the difference was statistically significant (P＜0.05).Conclusion Both Agomelatine and Paroxetine can safely and effectively improve the symptoms of patients with depression, and the clinical efficacy is roughly the same, but Agomelatine has little effect on sexual function.

Key words： Depression Sexual dysfunction Safety Agomelatin

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	DU Li-hui
	HUANG Jin-rong
	ZOU Cheng-lin
	XU Chen-wen

Cite this article:

DU Li-hui,HUANG Jin-rong,ZOU Cheng-lin, et al. Clinical research of Agomelatin in the treatment of depression[J]. 中国当代医药, 2021, 28(10): 106-108转116.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I10/106

[1]	刘陈，彭洪兴，黄光彪，等.阿戈美拉汀联合rTMS 对首发抑郁症认知功能的影响[J].国际精神病学杂志，2019，46（1）：78-80.
[2]	张德伦，陈林.阿戈美拉汀与艾司西酞普兰治疗抑郁症有效性与安全性的对照研究[J].中国医院药学杂志，2019，39（9）：966-968.
[3]	曾俊，秦春莉，韩树红.阿戈美拉汀治疗抑郁障碍患者快感缺失的疗效研究[J].神经疾病与精神卫生，2019，19（6）：588-593.
[4]	陈德沈，徐大利，陈杰，等.盐酸舍曲林联合阿戈美拉汀治疗抑郁症伴失眠的效果以及对血清氧化应激因子水平的影响[J].中国临床药学杂志，2020，29（1）：12-16.
[5]	孔令明，牛威，姚高峰，等.抑郁症预后与circRNA 表达水平、社会支持、应对方式之间的关系[J].精神医学杂志，2017，22（4）：266-269.
[6]	王艳娇，蒋涛.临床护理用患者健康问卷抑郁量表与汉密尔顿抑郁量表的一致性研究[J].齐齐哈尔医学院学报，2018，39（17）：76-77.
[7]	刘兰英，骆利元，朱春青，等.文拉法辛防治不同中医证型重性抑郁障碍效果评价[J].浙江预防医学，2018，30（5）：459-462.
[8]	张伟，刘海燕.高压氧联合阿戈美拉汀治疗老年抑郁症患者68 例疗效观察[J].中华航海医学与高气压医学杂志，2020，27（3）：275-278.
[9]	周严灿.阿戈美拉汀治疗抑郁障碍的疗效及对脑源性神经营养因子的影响[J].中国临床药理学与治疗学，2019，24（6）：699-703.
[10]	钟古华，廖君兰，刘其贵.阿戈美拉汀联合重复经颅磁刺激治疗老年难治性抑郁症患者疗效及其对认知功能的影响[J].精神医学杂志，2018，19（2）：122-125.
[11]	李红丽，王飞.阿戈美拉汀与舍曲林治疗首发抑郁症的疗效比较[J].慢性病学杂志，2019，20（8）：1192-1193.
[12]	任姣娜.阿戈美拉汀与艾司西酞普兰治疗抑郁症伴睡眠障碍患者的疗效分析[J].云南医药，2020，41（3）：273-275.
[13]	魏昆岭，孙秀丽，张彦恒，等.阿戈美拉汀片与帕罗西汀片治疗抑郁症伴失眠症状的临床研究[J].中国临床药理学杂志，2019，35（23）：3009-3012.
[14]	付冰冰，王喜今，刘兰芬，等.阿戈美拉汀单药治疗抑郁症疗效和安全性的多中心开放性研究[J].精神医学杂志，2019，32（6）：401-405.
[15]	钟远惠，王铭闻，张颖，等.艾司西酞普兰联合阿戈美拉汀治疗抑郁症的临床效果观察[J].齐齐哈尔医学院学报，2019，40（22）：2822-2824.
[16]	李峥.阿戈美拉汀与文拉法辛治疗抑郁症的临床疗效比较分析[J].首都食品与医药，2019，26（22）：68-69.
[17]	翟倩，丰雷，张国富，等.阿戈美拉汀治疗抑郁症的研究进展[J].中国药房，2019，30（17）：2435-2440.
[18]	杨志，迟强，栾中山.阿戈美拉汀与文拉法辛治疗抑郁症的临床对照研究[J].神经损伤与功能重建，2015，10（4）：356-357.